Dec 18 (Reuters) - MetaVia Inc :
* METAVIA ANNOUNCES POSITIVE TOP-LINE RESULTS FROM ITS PHASE 2A CLINICAL TRIAL OF DA-1241 IN PATIENTS WITH PRESUMED MASH
* DA-1241 VERY WELL TOLERATED WITH NO DRUG-RELATED SERIOUS ADVERSE EVENTS
* DA-1241 SHOWS SIGNIFICANT REDUCTION IN ALT LEVELS AT WEEKS 4 AND 8
* DA-1241 100MG SHOWS SIGNIFICANT IMPROVEMENTS IN CAP SCORE AT WEEK 16
* DA-1241 100MG SHOWS SIGNIFICANT REDUCTIONS IN HBA1C AT WEEK 16
* EXPECTS END OF PHASE 2 MEETING WITH FDA IN FIRST HALF OF 2025
Source text: Further company coverage:
((Reuters.Briefs@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.